Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Valeant Pharmaceuticals (VRX.TO)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

May have an inventory problem so there could be a write down. Needs to report a couple of good clean quarters.

BUY

Management has shot itself in the foot so often, that the PR side is embarrassing. They have some good products. On an asset/value basis, it's reasonable.

BUY

In short term, it has run into some problems. Overshiped 5 of 6 drugs. Will do great things. Great long term buy.

WEAK BUY

Stock is cheap. We own. Upside of 20-25%

BUY

Been buying. Continue to see price recovery. Probably going to be a fair bit of upside.

WAIT

Stay away. Major down tend. Dont buy a stock which is under down trend line. Dont buy untill stock breaks downtrend.

PAST TOP PICK

(Top pick on Nov 20/03. Down 2%.) Had said “If I could buy this at $23 it would be a steal”. The next day it opened at $22.50. Would buy again at $23.50. Nibble at it now.

DON'T BUY

Lots of product issues. Wait and see if they can deliver on their promises. Wouldnt put money in Biolvail

DON'T BUY

Has a lot of product issues. Would wait to see if they can deliver on any of their promises.

DON'T BUY

The Pattison purchase has restored some of the confidence, but not sure if they are finished with all their problems. Caution.

BUY

A great trading stock, so not a long-term hold which is his style. Good management.

DON'T BUY

Had a terrible year last year because of accounting concerns. Too much uncertainty.

HOLD

The interest in this company by Jim Pattison is a major plus factor. You'll have to be patient as there will be ups and downs.

PAST TOP PICK

(A past top pick Oct 7/03. Down 33.7%.) Still likes the stock and feels it's undervalued.

BUY

Offers upside potential, risky factors associated with it. Down because of tax loss selling.

Showing 466 to 480 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)